Introduction
Tenidap sodium is currently being assessed for the treatment of rheumatoid arthritis (RA) and osteoarthritis. It has been shown to have anti-inflammatory and analgesic effects similar to non-steroidal antiinflammatory drugs (NSAIDs) but, in contrast to the NSAIDs, the action of tenidap is not mediated solely via the cyclo-oxygenase pathway with the suppression of prostaglandin synthesis [1] . It has also been demonstrated that tenidap inhibits production of cytokines, in particular interleukin-6, interleukin-1 and tumour necrosis factor [2] . In subjects with RA, serum concentrations of C-reactive protein and serum amyloid A have been found to be reduced rapidly and significantly during treatment with tenidap 120 mg day-' [3] .
A range of systemic and topical drugs has been reported as causing abnormal photosensitivity [4] . A number of different reaction patterns can be seen. These appear to be drug specific, and range from an abnormal immediate type reaction to the several days delayed onset pattern as seen with psolarens. Different drugs have different subcellular targets and different methods of mediation.
The anti-rheumatic agent benoxaprofen was found to be capable of producing abnormal photosensitivity reactions in the skin [5] and, as a result of this and other side effects, approval was withdrawn. A subsequent review of data reported to the American Academy of Dermatology shows that photosensitivity is rare in the case of most NSAIDs. The majority of incidences are associated with the use of the phenylpropionic acids including ketoprofen, tiaprofenic acid, naproxen and, in particular, benoxaprofen [6] . The oxicam, piroxicam, unlike other NSAIDs, does not absorb radiation although its metabolite, an hydroxylated derivative, does and induces photosensitivity. Other NSAIDs, namely ibuprofen, which is a substituted phenylpropionic acid, and aspirin do not absorb radiation above 310 nm [7] and there does not appear to be any evidence of phototoxicity in these widely used NSAIDs.
Although there are no strong pointers from the chemical structure of tenidap to suggest any tendency to cause photosensitivity reactions, in the interests of safety it was considered prudent to investigate tenidap for this in healthy volunteers. A range of wavelengths of ultraviolet and visible light were used, and the degree of photosensitivity was assessed by determining any changes in the minimal erythema dose (MED).
Methods

Subjects
All subjects included in the study were healthy males or females of non-child-bearing potential; written informed consent was given by all participants. None of the subjects had a history of photodermatosis and all had skin types I-IV. Volunteers were excluded from the study if they had widespread cutaneous lesions on the mid/upper back, such as birthmarks or moles. Subjects with active skin disorders, such as eczema or psoriasis, were also excluded. In the 3 months prior to the study subjects should not have been sunburnt, used a sunbed or undergone phototherapy. Any volunteer using u.v.-absorbent emollients or sunscreens, taking prescription therapy, over-the-counter drugs or recreational drugs was also excluded from the study.
Study design
The single-centre study was placebo-controlled, double-blind and parallel-group in design. The study protocol was reviewed, had Dundee District Ethics Committee approval and was conducted in accordance with the Declaration of Helsinki (1964) and the Tokyo (1975) and Venice (1983) revisions.
Subjects were randomised according to a computergenerated randomisation schedule to take identicallooking capsules containing 40 or 120 mg tenidap sodium, or placebo together with 150 ml water once daily in the late afternoon for 7 days. For 3 days immediately preceding the administration of tenidap or placebo, photosensitivity was determined on specific areas of the mid/upper back. Photosensitivity was also determined on days 5-7 of drug treatment, testing being performed 2 h after tenidap or placebo administration.
Each subject was tested for photosensitivity by measuring the MED, according to the method of Ferguson et al. [8] . Different areas within a specific region of the mid/upper back were used for each wavelength (305, 335, 365, 400, 430 and 460 nm) and intensity of radiation at each time point and on each occasion; the order of usage of the different skin areas was recorded using a cellophane mapping technique. A diffraction grating monochromator with a 1.6 kW xenon arc was used and the irradiation dose at each wavelength was increased in increments of approximately 20% using normal light dose ranges (Table 1) . The irradiated area was examined visually 0, 5, 10, 15 and 30 min later for evidence of erythema when assessing immediate photosensitivity, and 24 and 48 h after the final dose given on day 7 in the case of delayed photosensitivity.
All MEDs were presented as lying within a range, the lower value being the largest dose that failed to 
Results
A total of 34 subjects were screened for entry into the study, but five were excluded because clinical laboratory tests were outside the normal range, two because of positive cannabinoid tests and three subjects failed to undergo baseline photosensitivity testing. All the 24 remaining study entrants except one completed all parts of the study. The exception did not undergo delayed photosensitivity testing 48 h after the last dose. The 24 subjects evaluated were aged 20-43 years; 21 were males and all subjects were Caucasian. The tenidap and placebo treatment groups were well matched for age, sex and weight (Table 2) .
Photosensitivity
Using the definition of increased photosensitivity as being a change from the baseline range such that the endpoint light dose range did not overlap the baseline range (Table 1) , no statistically significant increase in photosensitivity was detected in any of the 24 subjects completing the study. There were also no statistically Lack ofphotosensitising potential of tenidap, a novel anti-rheumatic agent 65S significant differences between treatment groups at any of the wavelengths tested (305-460 nm) when photosensitivity changes were classified as decreased, increased, or unchanged even if the baseline and final light dose ranges shared a common endpoint (Table 3) .
Safety
Although one subject reported mild abdominal discomfort after 3 days administration of tenidap sodium 40 mg this event was not considered to be drugrelated. Similarly, there were no treatment-related laboratory abnormalities, nor were there any clinically significant electrocardiographic abnormalities or variations in blood pressure or heart rate recorded up to 28 days after completion of test drug administration.
Discussion
Photosensitivity can be a clinically significant sideeffect in the treatment of RA patients using certain agents, such as NSAIDs [6] and has proved a particular problem with benoxaprofen [5, 9] . Although the initial clinical study of benoxaprofen reported a 9% incidence of phototoxicity, other studies indicated that this adverse effect could significantly restrict the lifestyle of many patients. Ferguson et al. [8] found that most Caucasian subjects would respond abnormally providing that enough drug and irradiation were present, and Halsey & Cardoe [9] reported that about 50% of a series of 300 benoxaprofen-treated patients experienced photosensitivity during the summer months.
The phototoxic response is dependent on the wavelength of the radiation, the effect being maximal in sensitive patients given benoxaprofen when exposed to radiation in the range 310-325 nm [8] . Similarly, Hindson et al. [10] found that wavelengths of 310-330 nm were most effective in producing photosensitisation and pointed out that these wavelengths corresponded to the absorption spectrum of benoxaprofen.
The phototoxicity of a wide range of NSAIDs has also been assessed in healthy subjects, who had received nabumetone, naproxen, ketoprofen and piroxicam, and the skin response to radiation was compared with that observed in placebo-treated subjects [11] . Only nabumetone and naproxen were shown to induce any phototoxicity, which in all cases was mild and occurred at the end of the dosing period, immediately after irradiation. This study also revealed that naproxen and the major metabolite of nabumetone, 6-methoxy-2-naphthylacetic acid, had similar absorption spectra to benoxaprofen. A study was also conducted in healthy student volunteers by Kligman & Kaidbey [12] , who found that the phototoxic effect of benoxaprofen was maximal at the terminal u.v.B wavelengths (290-320 nm) and in the u.v.A region (320-400 nm). Their study also showed that Caucasian subjects were most photosensitive, whereas subjects with dark skins and those using broad spectrum sunscreens were more protected. The wavelengths (305-460 nm) selected in the present study were within the range previously shown to induce photosensitivity in rheumatoid arthritis patients and healthy volunteers [10, 12] . In addition, the subjects included in the current double-blind study were not dark-skinned and had not been using sunscreens, hence they were not likely to be protected from any possible effects of radiation. No significant phototoxic effects, i.e. no immediate or delayed photosensitisation, were detected in these healthy subjects receiving either dose of tenidap compared with placebo, suggesting that tenidap is unlikely to result in photosensitisation in arthritis patients. When clinical and laboratory tests performed before, during and after administration of tenidap in the present study were compared with those in placebo-treated subjects, no tenidap-related adverse events were detected, and tenidap was well tolerated.
In conclusion, this study has failed to demonstrate a photosensitising potential for tenidap sodium when given for 1 week at daily doses of 40 or 120 mg.
